OakChart

Evotec SE ADR

EVOHealthcare·Drug Manufacturers - Specialty & Generic·Germany·Small·NASD·Nov 11 • 3:59 PM ET

1.690.00 (0.00%)
2026-11-11 23:37 CET
Market cap
600.26 USD m
Revenue, TTM
834.63 USD m
Net income, TTM
-210.64 USD m
Free cash flow, TTM
-144.51 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

EVO against its 20, 50 and 200-day averages
2050200beatearnings
1.502.002.503.00689K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EVOclose 1.6920-day 1.5750-day 1.61200-day 2.441.6952w low

56.3% under the 52-week high of 3.87 on 13 Jan 2026. 52-week low 1.33 on 13 Oct 2026. Last 15 sessions, 21.3% high to low

Volume 0.58× normal · the line is the 50-bar volume average

Profile

EVO
52-week range, 14% of the way up
1.333.87

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just-Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just-Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.

Employees4553
IPOFeb 05, 2004
Beta2.00
ATR, 14d0.07
Rel volume0.58
Short float0.02%
Insider own5.17%
Inst own0.91%

Snapshot

6 groups

Valuation

Index-
Market Cap600.25M
Enterprise Value692.12M
Income-210.64M
Sales834.63M
Book/sh2.05
Cash/sh1.28
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJan 11, 2019
Dividend Gr. 3/5Y- -
Payout-
Employees4553
IPOFeb 05, 2004

Ratios

P/E-
Forward P/E-
PEG-
P/S0.72
P/B0.82
P/C1.32
P/FCF-
EV/EBITDA-
EV/Sales0.83
Quick Ratio2.19
Current Ratio2.32
Debt/Eq0.75
LT Debt/Eq0.65
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.59
EPS next Y-0.21
EPS next Q-0.13
EPS this Y-137.17%
EPS next Y73.52%
EPS next 5Y-
EPS past 3/5Y14.30% -
Sales past 3/5Y4.05% 9.27%
EPS Y/Y TTM-19.37%
Sales Y/Y TTM0.31%
EPS Q/Q38.96%
Sales Q/Q-0.93%
EarningsNov 05 BMO
EPS/Sales Surpr.0.00% 12.43%

Ownership

Insider Own5.17%
Insider Trans0.00%
Inst Own0.91%
Inst Trans-3.27%
ROA-11.11%
ROE-25.24%
ROIC-17.51%
Gross Margin13.23%
Oper. Margin-15.41%
Profit Margin-25.24%
SMA207.88%
SMA505.09%
SMA200-30.83%
Trades-

Technical

Shs Outstand355.18M
Shs Float336.82M
Short Float0.02%
Short Ratio0.60
Short Interest0.06M
52W High3.87 -56.33%
52W Low1.33 27.07%
Volatility5.09% 3.48%
ATR (14)0.07
RSI (14)56.47
Beta2.00
Rel Volume0.58
Avg Volume105.73K
Volume61,506

Performance

Perf Week7.64%
Perf Month25.65%
Perf Quarter-16.34%
Perf Half Y-37.75%
Perf YTD-45.13%
Perf Year-43.10%
Perf 3Y-81.89%
Perf 5Y-92.81%
Perf 10Y-38.93%
Recom2.33
Target Price2.47
Prev Close1.69
Price1.69
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 16, 2026DowngradeBBerenbergBuy → Hold
Jul 15, 2026DowngradeTTD CowenBuy → Hold$2+18.3%
Apr 15, 2026ResumedHH.C. WainwrightBuy$7+314.2%
Feb 03, 2026InitiatedBBerenbergBuy
Apr 24, 2025UpgradeDDeutsche BankSell → Hold
Oct 07, 2024DowngradeJJefferiesBuy → Hold
Aug 08, 2024DowngradeDDeutsche BankHold → Sell
Jul 29, 2024DowngradeMMorgan StanleyOverweight → Equal-Weight$15 → $6+255.0%
Jul 11, 2024DowngradeDDeutsche BankBuy → Hold
Apr 12, 2024UpgradeDDeutsche BankHold → Buy

Peers

Mkt cap
TickerCompanyMkt cap
CRLCharles River Laboratories International Inc16.42B
RXRXRecursion Pharmaceuticals Inc2.24B
SDGRSchrodinger Inc2.37B
ALVOAlvotech1.92B
ABCLAbCellera Biologics Inc3.90B
DNAGinkgo Bioworks Holdings Inc679.14M
ABSIAbsci Corp1.74B
CERTCertara Inc1.79B
TMOThermo Fisher Scientific Inc265.92B
TWSTTwist Bioscience Corp8.07B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.178-0.178-0.087185.29164.812
2026Q22026-08-13-0.150-0.040-0.153165.66164.172
2026Q12026-05-06-0.398-0.144-0.402179.21204.392
2025Q42026-04-080.0470.1810.048297281.61
2025Q32025-11-05-0.138-0.077-0.142188.13218.44
2025Q22025-08-13-0.143-0.074-0.139200.13227.363
2025Q12025-05-06-0.102-0.045-0.094226.83245.691
2024Q42025-04-17-0.1310.016-0.123251.62232.882
2024Q32024-11-06-0.118-0.060-0.123198.54208.773
2024Q22024-08-13-0.298-0.038-0.288200.97220.084
2024Q12024-05-22-0.065-0.026-0.063227.08210.524
2023Q42024-04-24-0.0480.004-0.049215.16223.754
2023Q32023-11-08-0.118-0.029-0.120210.15190.793
2023Q22023-08-29-0.044-0.061-0.046179.99198.272
2023Q12023-05-120.127--0.042219.78-3
2022Q42023-03-280.063--0.079260.76-5

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.1380.1410.141493.67475.67
2020FY0.0240.0980.023589.86576.86
2021FY0.6860.8160.762671.98643.87
2022FY-0.492-0.381-0.523814.08773.56
2023FY-0.244-0.180-0.256835.23846.56
2024FY-0.630--0.598904.6-
2025FY-0.339-0.247-0.340922913.9
2026FY--0.804--675.57
2027FY--0.213--791.11
2028FY-0.006--850.31
2029FY-0.155--923.04
2030FY-0.317--1,059

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05302150.07148.08151.42
2026Q4S2026-10-29202156.41150.7162.12
2026Q4S2026-10-23101162.12162.12162.12
2026Q4S2026-10-13201172.72162.12183.33
2026Q4S2026-09-28200175.26167.2183.33
2026Q4S2026-09-27201175.26167.2183.33
2026Q4S2026-08-13202175.26167.2183.33
2026Q4S2026-08-08202175.7168.07183.33
2026Q4S2026-07-15302196.51168.07238.13
2026Q4S2026-07-14311224.28168.07266.64
2026Q4S2026-05-06320251.83238.13266.64
2026Q4S2026-05-01311233.2226.89238.13
2026Q4S2026-04-30311233.46227.68238.13
2026Q4S2026-04-14211231.12227.68234.57

Estimate history

EPS, annual0.090.3310.1410.0230.762-0.523-0.256-0.598-0.329-0.5929
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.123-0.123-0.094-0.139-0.1420.048-0.402-0.153-0.087
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual297.51442.884499.674571.041730.504789.753844.812862.072889.74834.63
Period201720182019202020212022202320242025TTM
Sales, quarterly203.11235.982210.469194.087191.523294.793183.262166.824189.751
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual294.566297.626301.305327.33352.717353.405353.872354.772354.978355.18
Period201720182019202020212022202320242025MRQ
Shares, quarterly354.607354.772355.192355.198355.208354.978355.117355.18355.18
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue834.63889.74862.07844.81789.75730.50571.04499.67442.88
Cost of Goods Sold Incl. D&A724.20816.12790.83655.56606.81551.38427.70350.94310.73
Gross Profit110.4373.6371.24189.25182.94179.12143.34148.74132.15
Selling, General and Administrative Excl. Other239.06232.61256.25305.02255.13219.20166.93143.08114.25
Research and Development45.9187.33104.70121.6680.5585.3472.9065.4042.02
Other Operating Expense--0.000.000.00----
Operating Income-128.64-158.99-185.01-115.77-72.19-40.08-23.595.6517.90
Interest Expense15.3516.3012.6512.6913.8210.949.658.302.91
Unusual Expense81.521.48101.0815.30189.03-237.400.6412.903.00
Net Income Before Taxes-187.76-143.66-255.85-112.26-190.11261.8712.5134.1961.13
Income Taxes20.71-28.06-48.42-43.98-22.28-12.45-6.54-9.95-42.87
Consolidated Net Income-210.64-116.83-212.10-90.72-184.61254.737.1641.6799.17
Net Income From Continuing Operations-210.64-116.83-212.10-90.72-184.61254.737.1642.6199.30
Net Income-210.64-116.83-212.10-90.72-184.61254.737.1642.6199.30
EPS (Recurring)-0.43-0.33-0.40-0.23-0.150.260.020.170.34
EPS (Basic, Before Extraordinaries)-0.59-0.33-0.60-0.26-0.520.770.020.140.34
EPS (Diluted)-0.59-0.33-0.60-0.26-0.520.760.020.140.33
EBITDA-19.47-46.72-75.09-7.7413.6339.8340.3260.2854.82
Non-Operating Income (Expense)37.7433.1042.8931.5084.9275.4846.3849.7449.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-3.043.887.328.866.464.222.863.52
Price To Earnings Ratio-----29.96815.4490.3730.10
Price To Sales Ratio0.731.231.714.913.6210.879.967.796.74
Gross Margin13.238.278.2622.4023.1624.5225.1029.7729.84
Operating Margin-15.41-17.87-21.46-13.70-9.14-5.49-4.131.134.04
Net Margin-25.24-13.13-24.60-10.74-23.3834.871.258.5322.42
Shares Outstanding355.18354.98354.77353.87353.41352.72327.33301.31297.63
Market Capitalization600.26600.261,475.164,150.922,859.052,080.056,005.683,871.772,963.61

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue189.75166.82183.26294.79191.52194.09210.47235.98
Cost of Goods Sold Incl. D&A166.98168.66185.10203.47191.60184.35181.82186.81
Gross Profit22.77-1.84-1.8391.33-0.079.7428.6549.17
Selling, General and Administrative Excl. Other55.3757.6163.0263.0659.6356.4761.5263.61
Research and Development10.7511.9311.7911.4410.189.3111.3210.38
Other Operating Expense0.00-0.00-0.000.000.000.00
Operating Income-32.60-59.45-64.8628.26-59.70-46.73-32.87-14.44
Interest Expense4.493.463.024.372.676.802.534.71
Unusual Expense-6.26-4.1387.494.41-1.66-1.420.2017.49
Net Income Before Taxes-24.91-54.94-142.6134.70-50.77-48.48-30.82-13.93
Income Taxes5.43-1.71-0.2917.270.150.071.8226.64
Consolidated Net Income-30.77-54.24-142.6617.02-50.35-49.28-33.23-43.56
Net Income From Continuing Operations-30.77-54.24-142.6617.02-50.35-49.28-33.23-43.56
Net Income-30.77-54.24-142.6617.02-50.35-49.28-33.23-43.56
EPS (Recurring)-0.10-0.16-0.230.06-0.14-0.14-0.09-0.09
EPS (Basic, Before Extraordinaries)-0.09-0.15-0.400.05-0.14-0.14-0.09-0.12
EPS (Diluted)-0.09-0.15-0.400.05-0.14-0.14-0.09-0.12
EBITDA-7.43-31.03-36.9955.97-30.12-18.16-6.40-
Non-Operating Income (Expense)5.923.8412.7615.229.943.624.7922.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio0.731.191.031.231.551.771.401.71
Gross Margin12.00-1.10-1.0030.98-0.045.0213.6120.84
Operating Margin-17.18-35.63-35.399.59-31.17-24.08-15.62-6.12
Net Margin-16.22-32.51-77.845.77-26.29-25.39-15.79-18.46
Shares Outstanding355.18355.18355.12354.98355.21355.20355.19354.77
Market Capitalization600.26994.66888.551,094.091,289.411,491.811,185.791,475.16

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments559.50410.89667.33766.81975.98589.67359.22170.84109.46
Short Term Receivables250.76226.13225.41294.32218.00167.48139.3493.0684.03
Inventories34.4332.2334.1231.8329.3316.6212.076.476.69
Other Current Assets51.3536.9370.8152.9228.6832.3616.4215.1513.30
Total Current Assets896.04706.17997.681,145.881,251.99806.13527.05285.52213.48
Net Property, Plant & Equipment651.38853.19890.97693.93551.08412.70268.53103.4891.34
Total Investments and Advances61.8143.65156.96160.44326.3972.2246.3133.1426.59
Intangible Assets356.96320.27321.55318.72327.99422.62418.59392.99426.86
Deferred Tax Assets79.58105.1067.2963.2066.4878.2892.8265.0041.37
Other Assets43.2939.16105.2079.0664.6345.7326.5617.7118.94
Total Assets2,089.062,067.552,539.652,461.222,588.571,837.671,379.85897.84818.58
Short Term Debt Incl. Current Port. of LT Debt121.7748.33164.6917.4857.5536.7223.2765.07202.30
Accounts Payable76.0688.84148.38103.8282.5652.0635.1635.5931.31
Income Tax Payable12.428.826.159.5912.054.118.204.842.44
Other Current Liabilities222.03210.83193.98229.52216.88162.17134.25118.8755.68
Total Current Liabilities432.28356.82513.19360.42369.04255.06200.88224.37291.73
Long Term Debt404.02406.69527.04523.27525.74565.23496.5665.7825.77
Provision for Risks Charges21.1820.2817.7417.5320.4925.3725.3022.8520.46
Deferred Tax Liabilities93.42102.1871.5071.9566.8673.3978.0840.0646.72
Other Liabilities182.50195.24173.07221.0439.7432.2243.5859.0835.33
Total Liabilities1,133.401,081.211,302.541,194.201,021.86951.26844.39412.14420.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity955.65986.341,237.111,267.021,566.70886.41535.47484.70397.37
Total Shareholders Equity955.65986.341,237.111,267.021,566.70886.41535.47484.70397.37
Accumulated Minority Interest0.000.000.000.000.000.000.001.001.19
Total Equity955.65986.341,237.111,267.021,566.70886.41535.47485.70398.56
Total Liabilities & Stockholders Equity2,089.062,067.552,539.652,461.222,588.571,837.671,379.85897.84818.58
Book Value Per Share2.692.783.503.594.442.711.781.631.35
Tangible Book Value Per Share1.691.882.592.683.511.420.390.31-0.10
Full-Time Employees4,5534,8275,0004,9524,1983,5723,0302,6172,178
Price to Book Ratio0.821.363.442.385.356.797.236.116.28
Return on Assets-5.62-9.21-3.63-7.3111.510.443.7411.564.44
Return on Equity-12.03-19.08-7.25-13.0320.781.018.3522.528.51
Return on Invested Capital-8.59-15.23-5.14-10.3112.170.494.1318.046.26
Quick Ratio1.991.891.883.093.313.102.561.240.71
Current Ratio2.071.981.943.183.393.162.621.270.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-211.27-116.83-212.10-90.72-184.61254.737.1641.6799.17
Depreciation-112.27109.92100.5285.8279.9163.9054.6236.92
Other Funds (Non Cash)47.7945.95201.1342.62178.79-193.4513.4520.44-5.80
Funds from Operations-34.1457.9793.1947.4688.12147.1893.05124.2499.47
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-71.09-68.62-73.78-10.75125.34-2.70-42.07-76.9984.86
Income Taxes Payable----30.8922.2817.6513.827.60
Cash from Operating Activities-105.23-10.6519.4136.70213.46144.4850.9847.25184.32
Capital Expenditures-52.65-93.25-143.04-233.52-190.60-140.59-112.94-35.71-32.88
Net Assets From Acquisitions-0.000.002.26-21.920.00-12.46-45.100.00
Sale of Fixed Assets and Businesses252.14251.16-10.280.570.000.000.000.0021.31
Purchase or Sale of Investments65.9729.9165.51205.11-220.16-138.44-44.28-15.99-32.08
Purchase of Investments-80.78-15.77-48.10-77.88-435.79-170.65-106.74-41.09-41.94
Sale Or Maturity of Investments146.7545.67113.62282.99215.6232.2162.4625.109.87
Other Uses0.000.000.000.00-4.34-9.20-7.12-0.17-2.52
Other Sources0.000.004.690.000.000.000.00-0.00
Cash from Investing Activities260.93187.82-83.11-25.57-437.02-288.23-176.80-96.96-46.16
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-1.59-1.490.400.240.73477.90286.782.131.86
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-1.59-1.490.400.240.73477.90286.782.131.86
Proceedsfrom Stock Options-1.75-1.750.000.000.37476.49284.960.000.00
Issuance or Reduction of Debt, Net--8.17-142.51115.73-35.8017.4617.12248.77-93.60
Change in Long Term Debt---0.00-----
Issuance of Long Term Debt---0.00-----
Reduction of Long Term Debt---0.00-----
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-21.00-36.35-168.2091.70-55.09470.94280.90236.46-91.74
Exchange Rate Effect-3.39-14.2810.670.70-20.01-0.0810.841.273.18
Net Change in Cash131.32126.55-221.23103.52-298.66327.11165.92188.0149.59
Free Cash Flow-144.51-92.52-107.65-193.9222.863.89-61.9612.19151.45
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----125.042,038.99-319.3819.71
Deferred Taxes & Investment Tax Credit-16.58-5.77-4.978.125.998.557.51-30.81

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments455.40532.31512.46559.50278.79408.50
Short Term Receivables194.54190.31192.48250.76226.36197.89
Inventories42.8344.0938.0034.4336.6440.57
Other Current Assets60.5966.6376.6051.35390.1262.56
Total Current Assets753.37833.34819.53896.04931.91709.53
Net Property, Plant & Equipment504.93514.23611.63651.38664.14918.77
Total Investments and Advances44.5448.6461.4261.8158.7762.03
Intangible Assets348.97350.43351.89356.96353.15357.20
Deferred Tax Assets0.132.161.9479.5813.0719.52
Other Assets57.4950.7242.9743.2961.8855.58
Total Assets1,709.421,799.531,889.392,089.062,082.922,122.62
Short Term Debt Incl. Current Port. of LT Debt73.3870.36102.10121.77113.83125.44
Accounts Payable55.1856.1763.2676.0658.1468.06
Income Tax Payable9.8910.1710.9712.428.259.50
Other Current Liabilities185.99220.53311.49222.03259.78246.79
Total Current Liabilities324.45357.24487.81432.28440.00449.80
Long Term Debt473.88473.69344.33404.02455.60416.97
Provision for Risks Charges31.1029.9973.9421.1821.4422.27
Deferred Tax Liabilities13.6211.7414.6093.4216.0316.09
Other Liabilities137.54165.91162.61182.50209.70224.67
Total Liabilities980.591,038.571,083.291,133.401,142.761,129.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity728.83760.96806.10955.65940.16992.83
Total Shareholders Equity728.83760.96806.10955.65940.16992.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity728.83760.96806.10955.65940.16992.83
Total Liabilities & Stockholders Equity1,709.421,799.531,889.392,089.062,082.922,122.62
Book Value Per Share2.052.142.272.692.652.80
Tangible Book Value Per Share1.071.161.281.691.651.79
Full-Time Employees4,3794,4614,5264,5534,7884,759
Price to Book Ratio0.821.230.941.161.301.51
Return on Assets-11.11-11.74-11.29-5.57-8.20-7.95
Return on Equity-25.24-26.25-25.15-11.93-17.46-16.33
Return on Invested Capital-2.56-4.39-12.401.25-3.61-3.50
Quick Ratio2.192.211.601.992.031.49
Current Ratio2.322.331.682.072.121.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-30.00-54.46-142.6615.85-51.59-48.31
Other Funds (Non Cash)45.4925.9756.51-80.1883.457.84
Funds from Operations15.49-28.49-86.1565.0131.86-40.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-63.85-97.5883.646.70-107.2266.58
Cash from Operating Activities-48.35-126.07-2.5171.71-75.3626.11
Capital Expenditures-9.17-12.87-12.62-17.99-25.97-26.66
Net Assets From Acquisitions-0.14--0.45-0.450.00
Sale of Fixed Assets and Businesses-0.070.010.09252.100.00-0.08
Purchase or Sale of Investments16.2237.87-4.2116.0914.300.87
Purchase of Investments0.70-79.66-5.273.46-8.49-5.23
Sale Or Maturity of Investments15.53117.531.0612.6422.796.10
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.8520.17-16.74250.65-12.11-25.87
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.000.040.12-1.740.010.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.000.040.12-1.740.010.01
Proceedsfrom Stock Options0.000.000.00-1.750.000.00
Issuance or Reduction of Debt, Net-1.3369.39-14.27-41.51-6.70-5.09
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-12.6165.23-22.22-51.40-11.62-11.81
Exchange Rate Effect-2.80-5.565.66-0.68-2.25-8.22
Net Change in Cash-56.92-46.23-35.81270.27-101.34-19.78
Free Cash Flow-55.10-136.73-7.3854.71-99.654.38
Price to Free Cash Flow-----45.04

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 862.29M 2025: 889.22M
Germany2024: 862.29M 2025: 889.22M
Consolidation, Policy2024: 15.63M 2025: 12.74M
Discovery & Preclinical Development2024: 648.19M 2025: 583.85M
Just-Evotec Biologics2024: 198.47M 2025: 292.63M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.02%0.1M336.8M107.54K
2026-10-150.02%0.1M336.8M104.03K
2026-09-300.01%0.0M336.8M93.69K
2026-09-150.03%0.1M336.8M58.76K
2026-08-310.03%0.1M336.8M53.64K
2026-08-140.02%0.1M336.8M53.19K
2026-07-310.01%0.0M336.9M51.38K
2026-07-150.01%0.0M336.9M67.10K
2026-06-300.02%0.1M336.9M71.19K
2026-06-150.02%0.1M336.9M84.30K
2026-05-290.02%0.1M336.9M104.65K
2026-05-150.02%0.1M336.8M118.96K
2026-04-300.03%0.1M336.8M156.14K
2026-04-150.12%0.4M336.8M142.37K
2026-03-310.10%0.3M337.0M139.40K
2026-03-130.12%0.4M337.0M182.39K
2026-02-270.10%0.4M337.0M173.58K
2026-02-130.08%0.3M337.0M170.13K
2026-01-300.08%0.3M337.0M137.83K
2026-01-150.08%0.3M336.9M133.01K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-14SCHEDULE 13D/ASEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-05-01SCHEDULE 13D/ASEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-29SEC
2026-04-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-24SEC
2026-04-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-08SEC
2026-04-0820-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-07SEC
2026-04-06SCHEDULE 13D/ASEC
2026-03-30SCHEDULE 13DSEC
2026-03-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-10SEC
2026-02-17SCHEDULE 13G/ASEC
2026-01-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-16SEC
2026-01-16SCHEDULE 13GSEC
2026-01-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-13SEC
2026-01-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-08SEC
2026-01-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-06SEC
2026-01-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-02SEC
2026-01-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-01SEC
2025-12-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-08SEC
2025-11-14SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DCF Advisers, LLC0.30%
WCM INVESTMENT MANAGEMENT, LLC0.19%
ABC ARBITRAGE SA0.15%
Optiver Holding B.V.0.09%
MORGAN STANLEY0.06%
LPL Financial LLC0.05%
ENVESTNET ASSET MANAGEMENT INC0.04%
OLD MISSION CAPITAL LLC0.01%
Pathstone Holdings, LLC0.01%
Fore Capital, LLC0.01%

Funds

Fund% owned
American Funds Fundamental Investors0.94%
Capital Income Builder0.67%
New Perspective Fund0.56%
Income Fund of America0.37%
SMALLCAP World Fund Inc0.14%
Pacer Developed Markets International Cash Cows 100 ETF0.04%
Franklin International Low Volatility High Dividend Index ETF0.04%
New World Fund Inc0.04%
Roundhill Sports Betting & iGaming ETF0.01%
Franklin International Core Dividend Tilt Index ETF0.01%

OakChart. EVO. Cached 15 minutes.

Some panels did not load: insider.